share_log

Needham Reiterates Buy on ResMed, Maintains $236 Price Target

Benzinga ·  Jun 24 19:25

Needham analyst Mike Matson reiterates ResMed (NYSE:RMD) with a Buy and maintains $236 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment